Somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
== See also == Island of stability – Prediction in nuclear physics Superheavy element – Chemical elements with atomic numbers from 104 to 120 Transuranium element – Element whose atomic number is greater than 92 Extended periodic table – Periodic table of the elements with eight or more periods
== Histology == Gastric chief cells are epithelial cells which are found within the gastric unit or gastric gland, and form the base of the gastric unit. The gastric chief cell has an extensive network of lamellar rough endoplasmic reticulum organized around the nucleus. The gastric chief cell also contains many large secretory vesicles filled with digestive enzymes in the apical cytoplasm.
By failing to close on the enemy earlier and more forcefully, his critics argue, he squandered an opportunity to destroy the entire Japanese Mobile Fleet. "This is what comes of placing a non-aviator in command over carriers" was the common refrain. Admiral John Towers, a naval aviation pioneer and Deputy Commander-in-Chief Pacific Fleet, demanded that Spruance be relieved. The request was denied by Nimitz. Moreover, Spruance was supported in his decision by Admiral Kelly Turner and Admiral Ernest King, Chief of Naval Operations. Spruance's caution (in particular, his suspicion of a diversionary force) can be compared with Admiral William Halsey's headlong pursuit of an actual diversionary force at Leyte Gulf four months later. Halsey left the American invasion fleet weakly protected during the Battle off Samar, nearly resulting in a devastating attack on the landing force by Japanese heavy surface units. It was prevented only by the heroic and desperate attack of 5 small American surface ships, which put up such an intense fight that the 23-ship-strong Japanese fleet thought they were engaging a much larger force and withdrew. In addition, by focusing on defense first, the carrier forces under Spruance at Philippine Sea suffered no significant harm. This was in contrast to Leyte Gulf when Halsey's carriers were trying to neutralize the enemy airfields and attack the enemy fleet simultaneously, such that a Japanese bomber managed to evade the Combat Air Patrols to fatally cripple the light carrier USS Princeton. Likewise, during the carrier-based air raids, U.S.
Sources: en.wikipedia.org
=== Cancer therapy === In magnetic fluid hyperthermia, nanoparticles of different types like Iron oxide, magnetite, maghemite or even gold are injected in tumor and then subjected under a high frequency magnetic field. These nanoparticles produce heat that typically increases tumor temperature to 40-46 °C, which can kill cancer cells. Another major potential of magnetic nanoparticles is the ability to combine heat (hyperthermia) and drug release for a cancer treatment. Numerous studies have shown particle constructs that can be loaded with a drug cargo and magnetic nanoparticles. The most prevalent construct is the "Magnetoliposome", which is a liposome with magnetic nanoparticles typically embedded in the lipid bilayer. Under an alternating magnetic field, the magnetic nanoparticles are heated, and this heat permeabilizes the membrane. This causes release of the loaded drug. This treatment option has a lot of potential as the combination of hyperthermia and drug release is likely to treat tumors better than either option alone, but it is still under development.
Methadone, sold under the brand names Dolophine and Methadose, among others, is a potent synthetic opioid used medically to treat chronic pain and opioid use disorder. Prescribed for daily use, the medicine relieves cravings and opioid withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein. Side effects are similar to those of other opioids. These frequently include dizziness, sleepiness, nausea, vomiting, and sweating. Serious risks include opioid abuse and respiratory depression. Abnormal heart rhythms may also occur due to a prolonged QT interval. The number of deaths in the United States involving methadone poisoning declined from 4,418 in 2011 to 3,300 in 2015. Risks are greater with higher doses. Methadone is made by chemical synthesis and acts on opioid receptors. Methadone was developed in Germany in the late 1930s by Gustav Ehrhart and Max Bockmühl. It was approved for use as an analgesic in the United States in 1947, and has been used in the treatment of addiction since the 1960s. It is on the World Health Organization's List of Essential Medicines.
=== Bitterness === Partially hydrolyzed protein can contain peptides that taste bitter, as more and more hydrophobic side chains are exposed. With soy protein, maximum bitterness occur at a mean size of 2 to 4 kDa; further hydrolysis leads to reduced bitterness.
Sources: en.wikipedia.org
=== Seizures === Levetiracetam is an anti-epileptic drug than can be used to treat partial and generalized seizures. Levetiracetam inhibits P/Q channel-mediated glutamate release and decreases the excitatory post synaptic currents of both AMPA and NMDA receptors in the hippocampus, specifically the dentate gyrus, which is known to propagate seizure activities. The inhibition of glutamate release results in an anti-epileptic response in patients because it decreases the excitatory postsynaptic current. There are many different types of calcium channels, so to prove that the P/Q type calcium channels are directly involved, a P/Q type voltage gated calcium channel inhibitor, omega-agatoxin TK, was used to block the channel. When blocked, patients no longer benefited from the anti-epileptic effects from the drugs. When blockers for L type and N type calcium channels were used, the effects of Levetiracetam were still seen. This is strong evidence that the P/Q type calcium channels are involved in the Levetiracetam treatment which allow for relief from seizures.
Glyndŵr's Way – a 135-mile (217 km) extended loop through Powys between Knighton and Welshpool Sarn Sabrina Walk – a 25-mile (40 km) circular walking route from Llanidloes to the source of the River Severn Severn Way – described by the Long Distance Walkers Association as a 224-mile (360 km) waymarked long-distance trail Taff Trail – walking and cycle path that runs for 55 miles (89 km) between Cardiff Bay and Brecon Offa's Dyke Path – a long-distance footpath about 177-mile (285 km) Wye Valley Walk – a 136 miles (219 km) long-distance footpath from Chepstow to Rhayader
Alexander first came to Yugoslavia in 1991. He actively worked with the opposition to Slobodan Milošević and moved to Yugoslavia after Milošević had been deposed in 2000. On 27 February 2001, the parliament of the Federal Republic of Yugoslavia (FRY) passed legislation conferring citizenship on members of the Karađorđević family. The legislation may also have effectively annulled a decree stripping the family of its citizenship of the Socialist Federal Republic of Yugoslavia (SFRY) in 1947. The annulment was the topic of some debate. Notably, the FRY was not the successor of the SFRY; rather the FRY was a new state (and was admitted to the United Nations as a new state on that basis). Therefore, the jurisdiction of a new state to annul an action of a different former state was questioned. In effect, the Karađorđević family had FRY citizenship conferred upon them, not "restored" as such. The FRY legislation also addresses restoration of property to the Karađorđević family. In March 2001, the property seized from his family, including royal palaces, was returned for residential purposes with property ownership to be decided by parliament at some later date. He has lived since 17 July 2001 in the Royal Palace (Kraljevski Dvor) in Dedinje, an exclusive area of Belgrade. The Palace, which was completed in 1929, is one of two royal residences in the Royal Compound; the other is the White Palace, which was completed in 1936.
=== Classic genetic mutations === Drosophila genes are traditionally named after the phenotype they cause when mutated. For example, the absence of a particular gene in Drosophila will result in a mutant embryo that does not develop a heart. Scientists have thus called this gene tinman, named after the Oz character of the same name. Likewise changes in the Shavenbaby gene cause the loss of dorsal cuticular hairs in Drosophila sechellia larvae. This system of nomenclature results in a wider range of gene names than in other organisms.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.